The South Korean government has introduced a comprehensive support framework for pharmaceutical and biotech ventures, targeting the creation of ‘blockbuster drug candidate companies.’ This initiative is a follow-up to the ‘Everyone’s Startup Project’ announced at the National Startup Era Strategy Meeting on January 30. The policy responds to the rapid growth of the global pharmaceutical market, which is three times the size of the semiconductor industry, and leverages Korea’s achievements in pharmaceutical exports, global rankings, and technology transfer. The government aims to address gaps in funding and commercialization caused by the lengthy and high-risk nature of drug development.
The policy directly impacts promising pharma-bio ventures, private operators, and stakeholders such as research institutions, hospitals, and investors. Selected companies will receive integrated support packages covering R&D, commercialization funding, and infrastructure access without additional evaluation. The government will use the ‘Scale-Up TIPS Platform’ to jointly identify and invest in high-potential ventures, and connect policy funds to create a seamless investment ecosystem from candidate discovery to clinical trials and commercialization. Special emphasis is placed on minimizing funding gaps at the clinical entry stage.
Implementation began with a joint policy meeting held by the Ministry of SMEs and Startups and the Ministry of Health and Welfare at the Korea Pharmaceutical and Bio-Pharma Manufacturers Association on March 24, 2026. The strategy centers on the ‘4UP’ approach: Scale-Up, Speed-Up, Level-Up, and Synergy-Up. Key actions include expanding global open innovation, supporting technology transfer, enhancing infrastructure and regulatory frameworks, and launching new collaborative R&D projects such as AI-driven pharma-bio ventures. Programs like ‘K-Bio Technology Commercialization Relay’ will provide integrated support from strategy development to global expansion.
Frequently asked questions include: What is the main goal of this policy? The government aims to create a virtuous cycle connecting investment, R&D, commercialization, and global market entry for pharma-bio ventures. How will companies benefit? Selected ventures will receive package support for R&D, business development, and infrastructure, with priority access to follow-up funding and regulatory improvements. What are the expected outcomes? The policy is designed to foster globally competitive biotech firms and ensure that innovation translates into improved public health.
The South Korean government’s policy to support pharma-bio ventures is grounded in a clear understanding of industry challenges, particularly the funding gaps during clinical development. By leveraging integrated support packages and expanding global collaboration, the initiative is poised to accelerate innovation and commercialization. The inclusion of AI-driven projects and regulatory improvements demonstrates a forward-thinking approach. Overall, this policy is likely to strengthen South Korea’s position in the global pharmaceutical market and foster sustainable growth in biotech innovation.